Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

March 31, 2023

Talem, Xyphos sign agreement for potential cancer therapeutic candidates

ImmunoPrecise Antibodies (IPA) subsidiary, Talem Therapeutics has entered into a research collaboration and licence option agreement with Astellas Pharma’s wholly-owned subsidiary, Xyphos Biosciences.

Talem, Xyphos sign agreement for potential cancer therapeutic candidates